Samsung Biologics took part in PEGS Boston, the world's largest conference for protein and antibody therapeutics, to broaden its global client base. The company aims to strengthen its global order-winning competitiveness by leveraging its anticancer drug development support platform and contract research and development (CRDO) capabilities.
Samsung Biologics said it is participating in the 2026 PEGS (Protein & Antibody Engineering Summit) Boston, held in Boston, Massachusetts, from the 11th (local time) to the 15th.
PEGS Boston is a global biopharmaceutical technology conference attended by more than 2,500 experts in the global biotech and pharmaceutical industries, where the latest protein and antibody therapeutic technologies and development strategies are shared.
During the event, Samsung Biologics is operating a separate meeting room and holding business meetings with global pharmaceutical companies.
On the 12th, the company held a luncheon presentation on the theme of "advancing anticancer drug development based on Samsung Organoid and integrated contract development (CDO) capabilities." The presentation was delivered by Kim Se-hee, head of the Organoid Technology Group at the CDO Development Center of Samsung Biologics.
At the event, Samsung Biologics introduced its anticancer drug development strategy using "Samsung Organoid," which models patients' tumors in a way similar to reality, and the candidate evaluation platform "DEVELOPICK®."
Samsung Organoid is a platform that analyzes drug responses in advance based on cells derived from cancer patients. The company said it can reduce the risk of failure in new drug development by evaluating the efficacy and development potential of candidates at an early stage.
DEVELOPICK is a platform that analyzes candidate characteristics with only small amounts of protein to select optimal candidates. Samsung Biologics has completed development up to version 3.0.
In addition, the company said it has built a total of nine CDO platforms to provide customized services to clients, including the high-concentration formulation development platform "S-HiCon™," the cell line platform "S-CHOice®," and the bispecific antibody platform "S-DUAL®."
James Choi, executive vice president in charge of sales support at Samsung Biologics, said, "We are continuously strengthening our capabilities to improve clients' chances of success from early candidate discovery to clinical development and commercialization," adding, "We will actively respond to global client demand based on our differentiated platforms."
Meanwhile, Samsung Biologics has been expanding its participation in global conferences, following DCAT Week in March and the American Association for Cancer Research (AACR) in April. The company plans to continue its global order activities by participating in the 2026 BIO International Convention (BIO USA), the world's largest biotech and pharmaceutical exhibition, to be held in San Diego, the United States, in June.